Hyperactivation of MAPK signaling in BRAFV600E-mutant melanoma cells leads to increased c-Jun expression, resulting in mesenchymal-like phenotype and resistance to BRAF/MEK inhibitors (MAPKi) (49). This evidence concerns the gene MAP2K7 and melanoma.